2016-2026年泌尿生殖領域合作與授權協議

根據 319 項現有合作關係和許可協議的訊息，讓我們了解泌尿生殖領域合作關係的趨勢。

《2016-2026 年泌尿生殖系統合作與許可協議》提供了有關泌尿生殖系統領域資產、技術和開發計劃的 319 項合作協議的全面資訊。

泌尿生殖系統合作涵蓋了多種腫瘤和非腫瘤適應症、技術和開發階段，交易結構反映了多種科學、臨床和商業性策略。

本報告將這些趨勢匯總到一個資源中，使用戶能夠了解誰在合作、哪些泌尿生殖系統機會正在吸引關注、交易是如何構建的、披露了哪些財務條款，以及交易如何因治療適應症、技術和開發階段而異。

這份報告不只是簡單地列出了交易清單；它結合了全面的市場交易分析和財務基準、主要交易商的信息、詳細的交易記錄以及公開的合約文件。

本報告為泌尿生殖領域的業務發展、許可、研究和評估、公司策略、研發策略、競爭情報以及參與合作的法律團隊提供可操作的資訊和基準資源。

了解泌尿生殖領域合作的趨勢。

本報告分析了2016年至2026年泌尿生殖領域的交易情況，內容包括：

• 泌尿生殖領域合作的年度趨勢
• 按交易類型分類的交易趨勢
• 產業部門
• 合作關係發展階段
• 技術類型
• 適應症
• 泌尿生殖領域最活躍的交易商
• 根據已披露的交易金額，主要交易
• 泌尿生殖領域合作活動的趨勢
• 這使用戶能夠確定他們的活動集中在哪些方面，並了解哪些公司、技術、開發階段和治療領域正在吸引合作興趣。
• 泌尿生殖領域合夥企業的財務狀況基準分析
• 財務條款可能因所涉資產、開發階段、技術、授予的權利以及交易的整體結構而有很大差異。

本報告對已揭露的財務狀況進行了詳細分析，包括以下幾點：

• 交易總額
• 預付款
• 里程碑付款
• 版稅率
• 透過分析這些基準背後的具體交易，用戶可以更全面地了解所揭露的經濟數據背後的經濟狀況。
• 這為內部基準測試、機會評估、交易準備和談判提供了一個現實的基準。
• 財務基準只有在結合類似交易的結構和情況進行分析時，才能發揮其最大效用，而不僅僅作為平均值來考慮。本報告提供了建構這種背景所需的交易基本資訊。
• 確定泌尿生殖領域的關鍵交易商和未來合作夥伴。
• 本報告列出了泌尿生殖領域合作活動最活躍的公司，並提供交易歷史記錄，以便用戶可以調查這些公司過去的活動。

這使用戶能夠識別以下內容：

• 積極尋求泌尿生殖領域商機的公司
• 有前景的許可和合作夥伴
• 我們曾多次與相關機構就相關適應症合作
• 積極參與相關開發階段的公司
• 對特定技術或方法表現出興趣的交易商
• 競爭對手採取類似的外部創新策略
• 對於尋求泌尿生殖系統資產和技術合作夥伴的公司而言，過去的交易歷史可以提供有用的線索，因為它顯示了哪些組織對類似的機會表現出了興趣。
• 本研究比較了泌尿生殖系統不同適應症和標靶之間的合作趨勢。
• 泌尿生殖系統疾病領域涵蓋了各種腫瘤和非腫瘤治療機會，每種都有不同的臨床、競爭和商業性趨勢。
• 本報告按治療適應症和治療標靶分析合作關係，使用戶能夠根據具體的項目和策略關注事項，以及廣泛的市場層級基準，確定最相關的交易。
• 透過結合對技術和發展階段的分析，使用者可以對類似的交易和潛在的未來合作關係形成更集中的視角。
• 了解泌尿生殖領域合約的結構
• 本報告包括聯合研究、授權、開發、研發及其他合作交易。

根據交易詳情和資訊披露，用戶可以調查以下方面：

• 授予和保留的權利
• 研發職責
• 授權權
• 獨家版權
• 區域權利
• 智慧財產
• 發展和監管義務
• 負責生產和供應
• 商業化權利
• 金錢補償
• 里程碑和版稅
• 管治
• 合約期限和終止條款
• 這些例子為考慮泌尿生殖醫學領域夥伴關係的適當結構提供了有用的參考。
• 從實際合約文件中學習
• 本報告提供了公開可取得的選定泌尿生殖系統交易的基礎合約文件的存取權限。

這些合約提供的資訊遠比簡單的標題公告所能展現的要詳細得多，使用戶能夠檢驗公司如何記錄諸如以下事項：

• 權利範圍
• 發展義務
• 智慧財產
• 獨家版權
• 財務狀況
• 里程碑觸發條件
• 特許權使用費規定
• 商業化權利
• 合約終止及其他談判事項
• 對於泌尿生殖領域中準備和談判合作研究和許可協議的團隊來說，獲取實際的合約措辭可以深入了解類似交易在實踐中的結構。
• 泌尿生殖領域綜合性交易名錄。
• 本報告包含泌尿生殖領域 319 項合作研究和授權協議的綜合目錄，可作為識別相關領先交易的詳細資訊來源。

在以下條件下可以查看交易記錄：

• 公司
• 技術類型
• 治療適應症或標靶
• 合約揭露狀態
• 每筆交易都與其底層交易記錄相關聯，從而可以存取詳細的交易資訊和相關的合約文件（如有）。
• 誰該使用這份報告？
• 業務拓展與授權團隊
• 識別類似的泌尿生殖系統交易、潛在合作夥伴和相關交易結構。
• 研究與評估團隊
• 我們會篩選出那些積極探索泌尿生殖領域商機的公司，並考慮相關的適應症、技術和發展階段。
• 尋求合作夥伴的生技公司
• 找出對類似泌尿生殖系統相關資產或技術表現出明顯興趣的組織。
• 企業策略與研發策略團隊
• 我們將了解我們的競爭對手和潛在合作夥伴如何透過外部創新來建立其泌尿生殖系統產品組合。
• 競爭情報與市場情報團隊
• 按公司、適應症、目標、開發階段和技術追蹤合作趨勢，以了解不斷變化的策略重點。
• 法律及交易團隊
• 我們將仔細審查公開的合約和以往的合約結構，以幫助您準備和談判交易。
• 我們將整個市場中有關泌尿生殖區域的資訊轉化為公司特定的洞察。
• 符合資格的客戶將收到 Current Partnering 的報告，以及為高階主管量身訂製的合作關係簡報。
• 本簡報將把有關泌尿生殖系統領域交易的情報應用於您自己的資產、技術、適應症、目標或合作目標。
• 如有需要，我們可以提供相關的類似交易、潛在的未來合作關係、競爭對手的活動、發展階段分析、交易結構、財務基準、忠誠度分析、合約見解以及其他專門為您情況選擇的資訊。
• 請索取樣本或聯絡 Current Partnering 討論本報告的內容以及我們是否可以為貴公司提供客製化分析。

目錄

執行摘要

第1章：引言

第2章：泌尿生殖領域的交易趨勢

• 泌尿生殖領域合作的過往趨勢
• 泌尿生殖領域合夥關係依交易類型分類
• 泌尿生殖領域各行業的聯盟趨勢
• 泌尿生殖領域合作的發展階段
• 按技術類型分類的泌尿生殖領域合作
• 基於治療適應症的泌尿生殖醫學領域合作

第3章 泌尿生殖領域合作的財務條件

• 泌尿生殖系統合作的已揭露財務條款
• 泌尿生殖領域合夥企業中的重大交易金額
• 泌尿生殖領域合作的預付款
• 泌尿生殖領域交易的里程碑付款
• 泌尿生殖區域的專利費

第4章：泌尿生殖領域的主要交易與關鍵交易負責人

• 泌尿生殖領域合作最活躍的公司
• 泌尿生殖領域最活躍的交易商名單
• 泌尿生殖領域重大交易：以價值計

第5章：泌尿生殖領域合約文件目錄

• 泌尿生殖領域合夥交易，並提供相關合約文件。

第6章：基於治療標靶的泌尿生殖系統領域的交易

• 泌尿生殖區治療標靶的交易
• 交易目錄
• 交易目錄 - 泌尿生殖系統交易，依公司名稱排序（A-Z）
• 交易目錄 - 按技術類型分類的泌尿生殖系統交易
• 交易類型的定義
• 關於生物製藥研究
• Current Partnering
• Current Agreements
• 理想合作夥伴近期報告標題

Understand the genitourinary partnering landscape using intelligence from 319 real-world collaboration and licensing deals.

Genitourinary Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 319 partnering deals involving genitourinary assets, technologies and development programs.

Genitourinary partnering encompasses a diverse range of oncology and non-oncology indications, technologies and stages of development, with transaction structures reflecting different scientific, clinical and commercial strategies.

The report brings this activity together in one resource, enabling users to understand who is partnering, which genitourinary opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in genitourinary partnering.

Understand the genitourinary partnering landscape

The report analyzes genitourinary dealmaking from 2016 to 2026, including:

• Trends in genitourinary partnering by year
• Deal activity by deal type
• Industry sector
• Stage of development at the time of partnering
• Technology type
• Therapeutic indication
• Most active genitourinary dealmakers
• Leading deals by disclosed value
• How genitourinary partnering activity is evolving
• This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
• Benchmark genitourinary deal financials
• Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

• Headline deal values
• Upfront payments
• Milestone payments
• Royalty rates
• Users can investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
• This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
• Financial benchmarks are most useful when considered alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
• Identify leading genitourinary dealmakers and prospective partners
• The report identifies the most active companies in genitourinary partnering and provides transaction histories that enable users to investigate their previous activity.

This can help users identify:

• Companies actively seeking genitourinary opportunities
• Prospective licensing and collaboration partners
• Organizations repeatedly partnering in relevant indications
• Companies active at relevant stages of development
• Dealmakers demonstrating interest in specific technologies or approaches
• Competitors pursuing similar external innovation strategies
• For companies seeking to partner a genitourinary asset or technology, previous transaction activity can provide useful evidence of which organizations have demonstrated an appetite for comparable opportunities.
• Compare partnering activity across genitourinary indications and targets
• Genitourinary disease encompasses a range of distinct oncology and non-oncology opportunities with differing clinical, competitive and commercial dynamics.
• The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad market-level benchmarks and identify transactions most relevant to a particular program or strategic interest.
• Combined with analysis by technology and development stage, this enables users to develop a more focused view of comparable transactions and prospective partners.
• Understand how genitourinary agreements are structured
• The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

• Rights granted and retained
• Research and development responsibilities
• Licensing rights
• Exclusivity
• Geographic rights
• Intellectual property
• Development and regulatory obligations
• Manufacturing and supply responsibilities
• Commercialization rights
• Financial consideration
• Milestones and royalties
• Governance
• Term and termination provisions
• These real-world examples provide useful reference points when considering the appropriate structure for a genitourinary partnership.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying contract documents for selected genitourinary transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

• Scope of rights
• Development obligations
• Intellectual property
• Exclusivity
• Financial terms
• Milestone triggers
• Royalty provisions
• Commercialization rights
• Termination and other negotiated provisions
• For teams preparing or negotiating a genitourinary collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
• Comprehensive genitourinary deal directory
• The report includes a comprehensive directory of 319 genitourinary collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.

Deals can be reviewed by:

• Company
• Technology type
• Therapeutic indication or target
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable genitourinary transactions, prospective partners and relevant deal structures.
• Search and Evaluation teams
• Understand which companies are actively seeking genitourinary opportunities across relevant indications, technologies and development stages.
• Biotechnology Companies Seeking Partners
• Identify organizations with demonstrated interest in comparable genitourinary assets and technologies.
• Corporate and R&D Strategy teams
• Understand how competitors and prospective partners are building genitourinary portfolios through external innovation.
• Competitive and Market Intelligence teams
• Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
• Legal and Transaction teams
• Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
• Turn market-wide genitourinary intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying genitourinary deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in genitourinary dealmaking

• 2.1. Introduction
• 2.2. Genitourinary partnering over the years
• 2.3. Genitourinary partnering by deal type
• 2.4. Genitourinary partnering by industry sector
• 2.5. Genitourinary partnering by stage of development
• 2.6. Genitourinary partnering by technology type
• 2.7. Genitourinary partnering by therapeutic indication

Chapter 3 - Financial deal terms for genitourinary partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for genitourinary partnering
• 3.3. Genitourinary partnering headline values
• 3.4. Genitourinary deal upfront payments
• 3.5. Genitourinary deal milestone payments
• 3.6. Genitourinary royalty rates

Chapter 4 - Leading genitourinary deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in genitourinary partnering
• 4.3. List of most active dealmakers in genitourinary
• 4.4. Top genitourinary deals by value

Chapter 5 - Genitourinary contract document directory

• 5.1. Introduction
• 5.2. Genitourinary partnering deals where contract document available

Chapter 6 - Genitourinary dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by genitourinary therapeutic target
• Deal directory
• Deal directory - Genitourinary deals by company A-Z
• Deal directory - Genitourinary deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Genitourinary partnering since 2016
• Figure 2: Genitourinary partnering by deal type since 2016
• Figure 3: Genitourinary partnering by industry sector since 2016
• Figure 4: Genitourinary partnering by stage of development since 2016
• Figure 5: Genitourinary partnering by technology type since 2016
• Figure 6: Genitourinary partnering by indication since 2016
• Figure 7: Genitourinary deals with a headline value
• Figure 8: Genitourinary deals with upfront payment values
• Figure 9: Genitourinary deals with milestone payment
• Figure 10: Genitourinary deals with royalty rates
• Figure 11: Active genitourinary dealmaking activity since 2016
• Figure 12: Top genitourinary deals by value since 2016